-+ 0.00%
-+ 0.00%
-+ 0.00%

Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295

PUBT·08/26/2026 11:24:41
Listen to the news
Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295
  • Gubra disclosed AbbVie has started a Phase 2 trial of obesity drug candidate ABBV-295, triggering a USD 50 million milestone payment.
  • Earlier Phase 1 results have already been presented, indicating weight loss potential with acceptable safety and tolerability.
  • The Phase 2 study will test multiple dosing approaches in adults with obesity or overweight, with efficacy readouts expected later.
  • ABBV-295 targets amylin, positioning it as a distinct mechanism from GLP-1 or GIP-based weight-loss drugs.
  • The 2025 license deal leaves Gubra eligible for up to USD 1.875 billion in milestones, plus tiered royalties on global net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.